GeoVax Labs (GOVX) 10-Q 5 May 20 2020 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2020	May 05, 2020
Document Information [Line Items]
Entity Registrant Name	GeoVax Labs, Inc.
Entity Central Index Key	0000832489
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Interactive Data Current	Yes
Entity Common Stock, Shares Outstanding (in shares)		13,819,101
Entity Shell Company	false
Document Type	10-Q
Document Period End Date	Mar. 31, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q1
Amendment Flag	false
Title of 12(g) Security	Common Stock $.001 par value

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
ASSETS
Cash and cash equivalents	$ 221,807	$ 283,341
Grant funds and other receivables	520,509	68,603
Prepaid expenses and other current assets	67,895	95,320
Total current assets	810,211	447,264
Property and equipment, net (Note 5)	9,612	10,606
Deposits	11,010	11,010
Total assets	830,833	468,880
Current liabilities:
Accounts payable	740,829	152,653
Accrued expenses (Note 6)	1,917,425	1,851,040
Current portion of notes payable (Note 7)	12,048	12,500
Total current liabilities	2,670,302	2,016,193
Note payable, net of current portion (Note 7)	24,781	27,243
Total liabilities	2,695,083	2,043,436
Commitments (Note 8)
Stockholders’ equity (deficiency):
Preferred Stock, $.01 par value (Note 9): Authorized shares – 10,000,000 Issued and outstanding shares – 400 and 2,486 March 31, 2020 and December 31, 2019, respectively	376,095	1,932,433
Common stock, $.001 par value: Authorized shares – 600,000,000 Issued and outstanding shares – 13,791,601 and 299,835 at March 31, 2020 and December 31, 2019, respectively	13,792	300
Additional paid-in capital	41,189,070	39,340,224
Accumulated deficit	(43,443,207)	(42,847,513)
Total stockholders’ equity (deficiency)	(1,864,250)	(1,574,556)
Total liabilities and stockholders’ equity (deficiency)	$ 830,833	$ 468,880

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Mar. 31, 2020	Dec. 31, 2019
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock, shares issued (in shares)	400	2,486
Preferred stock, shares outstanding (in shares)	400	2,486
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	600,000,000	600,000,000
Common stock, shares issued (in shares)	13,791,601	299,835
Common stock, shares outstanding (in shares)	13,791,601	299,835

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Grant and collaboration revenues	$ 715,977	$ 364,232
Operating expenses:
Research and development	808,936	555,718
General and administrative	502,345	510,064
Total operating expenses	1,311,281	1,065,782
Loss from operations	(595,304)	(701,550)
Other income (expense):
Interest income	752	1,224
Interest expense	(1,142)	(1,128)
Total other income (expense)	(390)	96
Net loss	$ (595,694)	$ (701,454)
Basic and diluted:
Net loss per common share (in dollars per share)	$ (0.13)	$ (2,851.44)
Weighted average shares outstanding (in shares)	4,687,893	246

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficiency) (Unaudited) - USD ($)	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2018	3,450	219
Balance at Dec. 31, 2018	$ 1,971,333		$ 37,483,204	$ (40,476,884)	$ (1,022,347)
Sale of convertible preferred stock for cash (in shares)	500
Sale of convertible preferred stock for cash	$ 404,250		85,750		490,000
Conversion of preferred stock to common stock (in shares)	(767)	59
Conversion of preferred stock to common stock	$ (303,475)		303,475
Net loss				(701,454)	(701,454)
Stock-based compensation expense			26,652		26,652
Balance (in shares) at Mar. 31, 2019	3,183	278
Balance at Mar. 31, 2019	$ 2,072,108		37,899,081	(41,178,338)	(1,207,149)
Balance (in shares) at Dec. 31, 2019	2,486	299,835
Balance at Dec. 31, 2019	$ 1,932,433	$ 300	39,340,224	(42,847,513)	(1,574,556)
Sale of convertible preferred stock for cash (in shares)	300
Sale of convertible preferred stock for cash	$ 300,000				300,000
Conversion of preferred stock to common stock (in shares)	(2,386)	13,481,349
Conversion of preferred stock to common stock	$ (1,856,338)	$ 13,481	1,842,857
Issuance of common stock for services (in shares)		10,417			10,417
Issuance of common stock for services		$ 11	5,989		$ 6,000
Net loss				(595,694)	(595,694)
Balance (in shares) at Mar. 31, 2020	400	13,791,601
Balance at Mar. 31, 2020	$ 376,095	$ 13,792	$ 41,189,070	$ (43,443,207)	$ (1,864,250)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Cash flows from operating activities:
Net loss	$ (595,694)	$ (701,454)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	994	1,897
Stock-based compensation expense	6,000	153,224
Changes in assets and liabilities:
Grant funds and other receivables	(451,906)	(38,463)
Prepaid expenses and other current assets	27,425	(30)
Accounts payable and accrued expenses	654,561	267,465
Total adjustments	237,074	384,093
Net cash used in operating activities	(358,620)	(317,361)
Cash flows from investing activities:
Purchase of property and equipment		(4,272)
Net cash used in investing activities		(4,272)
Cash flows from financing activities:
Net proceeds from sale of preferred stock	300,000	240,000
Principal repayment of note payable	(2,914)	(2,083)
Net cash provided by financing activities	297,086	237,917
Net increase (decrease) in cash and cash equivalents	(61,534)	(83,716)
Cash and cash equivalents at beginning of period	283,341	259,701
Cash and cash equivalents at end of period	$ 221,807	$ 175,985

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) (Parentheticals)	3 Months Ended
	Mar. 31, 2019USD ($)shares
Conversion of Series C Preferred Stock Into Series F Preferred Stock [Member]
Convertible preferred stock (in shares)	1,563
Conversion of Series E Preferred Stock Into Series F Preferred Stock [Member]
Convertible preferred stock (in shares)	1,200
Conversion of Series C and Series E Preferred Stock Into Series F Preferred Stock [Member]
Conversion of stock, shares issued (in shares)	2,763
Series G Convertible Preferred Stock Issued in Exchange for Cancellation of Term notes Payable [Member]
Convertible preferred stock (in shares)	250
Convertible note, value | $	$ 250,000
Conversion of Series C Preferred Stock Into Common Stock [Member]
Convertible preferred stock (in shares)	587
Conversion of stock, shares issued (in shares)	39
Conversion of Series F Preferred Stock Into Common Stock [Member]
Convertible preferred stock (in shares)	180
Conversion of stock, shares issued (in shares)	20

Note 1 - Description of Busines

Note 1 - Description of Business	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Nature of Operations [Text Block]	1. GeoVax Labs, Inc. (“GeoVax” or the “Company”), is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and cancers using a novel patented Modified Vaccinia Ankara (MVA) Virus-Like Particle (VLP) vaccine platform (GV-MVA-VLP TM Our current development programs are focused on preventive vaccines against novel coronavirus (COVID- 19 Our corporate strategy is to improve the health of patients worldwide by advancing our vaccine platform, using its unique capabilities to design and develop an array of products addressing unmet medical needs in the areas of infectious diseases and oncology. We intend to advance products through to human clinical testing, and to seek partnership or licensing arrangements for commercialization. We also leverage third Certain of our vaccine development activities have been, and continue to be, financially supported by the U.S. government. This support has been both in the form of research grants and contracts awarded directly to us, as well as indirect support for the conduct of preclinical animal studies and human clinical trials. We operate in a highly regulated and competitive environment. The manufacturing and marketing of pharmaceutical products require approval from, and are subject to, ongoing oversight by the Food and Drug Administration (FDA) in the United States, by the European Medicines Agency (EMA) in the European Union, and by comparable agencies in other countries. Obtaining approval for a new pharmaceutical product is never certain, may one GeoVax is incorporated under the laws of the State of Delaware and our principal offices are located in the metropolitan Atlanta, Georgia area.

Note 2 - Basis of Presentation

Note 2 - Basis of Presentation	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Basis of Accounting [Text Block]	2. The accompanying condensed consolidated financial statements at March 31, 2020 three March 31, 2020 2019 not 10 December 31, 2019. not As described in Note 9, April 30, 2019, one five hundred January 21, 2020, one two thousand Our financial statements have been prepared assuming that we will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business for the twelve We believe that our existing cash resources together with our government and collaborative funding commitments, will be sufficient to continue our planned operations into the third 2020. not may not

Note 3 - Significant Accounting

Note 3 - Significant Accounting Policies and Recent Accounting Pronouncements	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Significant Accounting Policies [Text Block]	3. We disclosed in Note 2 10 December 31, 2019 no 10 There have been no three March 31, 2020, 10 December 31, 2019,

Note 4 - Basic and Diluted Loss

Note 4 - Basic and Diluted Loss Per Common Share	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Earnings Per Share [Text Block]	4. Basic and diluted loss per common share are computed based on the weighted average number of common shares outstanding. Common share equivalents consist of common shares issuable upon conversion of convertible preferred stock, and upon exercise of stock options and stock purchase warrants. All common share equivalents are excluded from the computation of diluted loss per share since the effect would be anti-dilutive. The weighted average number of common share equivalents which were excluded from the computation of diluted loss per share, totaled 970,571 295 March 31, 2020 2019, 9 March 31, 2020

Note 5 - Property and Equipment

Note 5 - Property and Equipment	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	5. Property and equipment as shown on the accompanying Condensed Consolidated Balance Sheets is composed of the following as of March 31, 2020 December 31, 2019: March 31, 2020 December 31, 2019 Laboratory equipment $ 534,577 $ 534,577 Leasehold improvements 115,605 115,605 Other furniture, fixtures & equipment 11,736 11,736 Total property and equipment 661,918 661,918 Accumulated depreciation and amortization (652,306 ) (651,312 ) Property and equipment, net $ 9,612 $ 10,606

Note 6 - Accrued Expenses

Note 6 - Accrued Expenses	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	6. Accrued expenses as shown on the accompanying Condensed Consolidated Balance Sheets is composed of the following as of March 31, 2020 December 31, 2019: March 31, 2020 December 31, 2019 Accrued management salaries $ 1,418,797 $ 1,323,483 Accrued directors’ fees 436,920 409,219 Other accrued expenses 61,708 118,338 Total accrued expenses $ 1,917,425 $ 1,851,040

Note 7 - Notes Payable

Note 7 - Notes Payable	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Debt Disclosure [Text Block]	7. On February 28, 2018, five $50,000. 5%, $8,964 2020 $12,487 2021, $13,126 2022, $2,252 2023. three March 31, 2020 2019 $485 $621,

Note 8 - Commitments

Note 8 - Commitments	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Commitments Disclosure [Text Block]	8. Lease Agreement We lease approximately 8,400 December 31, 2022. three March 31, 2020 2019 $41,539 $40,316, $124,616 2020, $171,213 2021 $176,356 2022, may ninety Other Commitments In the normal course of business, we enter into various firm purchase commitments related to production and testing of our vaccine, conduct of research studies, and other activities. As of March 31, 2020, $539,000 2020.

Note 9 - Stockholders' Equity

Note 9 - Stockholders' Equity	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Preferred Stock [Text Block]	9. Preferred Stock Summary 10,000,000 $.01 may one March 31, 2020 December 31, 2019. $1,000 three March 31, 2020 March 31, 2020 December 31, 2019 Carrying Carrying Shares Value Shares Value Series B Convertible Preferred Stock 100 $ 76,095 100 $ 76,095 Series H Convertible Preferred Stock - - 1,686 1,156,338 Series I Convertible Preferred Stock - - 700 700,000 Series J Convertible Preferred Stock 300 300,000 - - Total 400 $ 376,095 2,486 $ 1,932,433 Series B Preferred Stock -- no not March 31, 2020, 100 $350,000 no three March 31, 2020. Series H Preferred Stock – no not three March 31, 2020, 1,686 9,393,937 March 31, 2020, no Series I Preferred Stock – no not three March 31, 2020, 700 4,087,412 March 31, 2020, no Series J Preferred Stock – January 24, 2020, 300 $300,000. no not $2.00 80% ten may, three March 31, 2020, no 300 March 31, 2020. Common Stock Reverse Stock Split – January 3, 2020, January 21, 2020, one two thousand As discussed under “Preferred Stock” above, during the three March 31, 2020, 13,481,349 During the three March 31, 2020, 10,417 $6,000 Stock Options During the three March 31, 2020, no April 2019 January 2020, March 31, 2020 no three March 31, 2020. Stock Purchase Warrants The following table summarizes our stock purchase warrants outstanding as of March 31, 2020: Expiration Date Exercise Price Number of Warrants Series G September 2021 $ 25,440 48 Series H December 2021 1.15 217,392 Series I Aug-Dec 2024 15,000 48 All of the outstanding warrants contain anti-dilution and price adjustment provisions, which may, no April 30, 2019 January 21, 2020 Stock-Based Compensation Expense Stock-based compensation expense related to our stock option plans was $- 0 $26,652 three March 31, 2020 2019, March 31, 2020, no Additionally, during the three March 31, 2020 2019 $6,000 $126,572,

Note 10 - Income Taxes

Note 10 - Income Taxes	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Income Tax Disclosure [Text Block]	10. Because of our historically significant net operating losses, we have not 382

Note 11 - Grants and Collaborat

Note 11 - Grants and Collaboration Revenue	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Government Grants and Contracts [Text Block]	11. We receive payments from government entities under grants from the National Institute of Allergy and Infectious Diseases (NIAID) and from the U.S. Department of Defense in support of our vaccine research and development efforts. We record revenue associated with government grants as the reimbursable costs are incurred. During the three March 31, 2020 2019, $654,021 $354,319, March 31, 2020, $606,944 2020. During the three March 31, 2020 2019, $61,956 $9,913, third

Note 12 - Subsequent Events

Note 12 - Subsequent Events	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Subsequent Events [Text Block]	12. CARES Act Paycheck Protection Program Loan On April 17, 2020, $170,200 one April 17, 2022. No 180 November 17, 2020, $9,578.16 may may

Note 5 - Property and Equipme_2

Note 5 - Property and Equipment (Tables)	3 Months Ended
	Mar. 31, 2020
Notes Tables
Property, Plant and Equipment [Table Text Block]	March 31, 2020 December 31, 2019 Laboratory equipment $ 534,577 $ 534,577 Leasehold improvements 115,605 115,605 Other furniture, fixtures & equipment 11,736 11,736 Total property and equipment 661,918 661,918 Accumulated depreciation and amortization (652,306 ) (651,312 ) Property and equipment, net $ 9,612 $ 10,606

Note 6 - Accrued Expenses (Tabl

Note 6 - Accrued Expenses (Tables)	3 Months Ended
	Mar. 31, 2020
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	March 31, 2020 December 31, 2019 Accrued management salaries $ 1,418,797 $ 1,323,483 Accrued directors’ fees 436,920 409,219 Other accrued expenses 61,708 118,338 Total accrued expenses $ 1,917,425 $ 1,851,040

Note 9 - Stockholders' Equity (

Note 9 - Stockholders' Equity (Tables)	3 Months Ended
	Mar. 31, 2020
Notes Tables
Schedule of Preferred Stock [Table Text Block]	March 31, 2020 December 31, 2019 Carrying Carrying Shares Value Shares Value Series B Convertible Preferred Stock 100 $ 76,095 100 $ 76,095 Series H Convertible Preferred Stock - - 1,686 1,156,338 Series I Convertible Preferred Stock - - 700 700,000 Series J Convertible Preferred Stock 300 300,000 - - Total 400 $ 376,095 2,486 $ 1,932,433
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Expiration Date Exercise Price Number of Warrants Series G September 2021 $ 25,440 48 Series H December 2021 1.15 217,392 Series I Aug-Dec 2024 15,000 48

Note 2 - Basis of Presentation

Note 2 - Basis of Presentation (Details Textual)	Jan. 21, 2020	Apr. 30, 2019
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	2,000	500

Note 4 - Basic and Diluted Lo_2

Note 4 - Basic and Diluted Loss Per Common Share (Details Textual) - shares	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)	970,571	295

Note 5 - Property and Equipme_3

Note 5 - Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Property and equipment, gross	$ 661,918	$ 661,918
Accumulated depreciation and amortization	(652,306)	(651,312)
Property and equipment, net	9,612	10,606
Laboratory Equipment [Member]
Property and equipment, gross	534,577	534,577
Leasehold Improvements [Member]
Property and equipment, gross	115,605	115,605
Other Furniture Fixtures And Equipment [Member]
Property and equipment, gross	$ 11,736	$ 11,736

Note 6 - Accrued Expenses - Sch

Note 6 - Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Accrued management salaries	$ 1,418,797	$ 1,323,483
Accrued directors’ fees	436,920	409,219
Other accrued expenses	61,708	118,338
Total accrued expenses	$ 1,917,425	$ 1,851,040

Note 7 - Notes Payable (Details

Note 7 - Notes Payable (Details Textual) - USD ($)	Feb. 28, 2018	Mar. 31, 2020	Mar. 31, 2019
Interest Expense, Total		$ 1,142	$ 1,128
Senior Notes [Member]
Proceeds from Notes Payable, Total	$ 50,000
Debt Instrument, Interest Rate, Stated Percentage	5.00%
Long-Term Debt, Maturity, Remainder of Fiscal Year		8,964
Long-Term Debt, Maturity, Year Two		12,487
Long-Term Debt, Maturity, Year Three		13,126
Long-Term Debt, Maturity, Year Four		2,252
Interest Expense, Total		$ 485	$ 621

Note 8 - Commitments (Details T

Note 8 - Commitments (Details Textual)	3 Months Ended
	Mar. 31, 2020USD ($)ft²	Mar. 31, 2019USD ($)
Area of Real Estate Property (Square Foot) | ft²	8,400
Operating Leases, Rent Expense, Total	$ 41,539	$ 40,316
Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year	124,616
Lessee, Operating Lease, Liability, Payments, Due Year Two	171,213
Lessee, Operating Lease, Liability, Payments, Due Year Three	176,356
Unrecorded Unconditional Purchase Obligation, Total	$ 539,000

Note 9 - Stockholders' Equity_2

Note 9 - Stockholders' Equity (Details Textual)	Jan. 24, 2020USD ($)$ / sharesshares	Jan. 21, 2020	Apr. 30, 2019	Mar. 31, 2020USD ($)$ / sharesshares	Mar. 31, 2019USD ($)	Dec. 31, 2019$ / sharesshares
Preferred Stock, Shares Authorized (in shares)				10,000,000		10,000,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares				$ 0.01		$ 0.01
Preferred Stock, Shares Outstanding, Ending Balance (in shares)				400		2,486
Stock Issued During Period, Shares, Issued for Services (in shares)				10,417
Stock Issued During Period, Value, Issued for Services | $				$ 6,000
Conversion of Stock, Shares Converted | $				0
Stock Issued During Period, Value Expensed During the Period, Issued for Services | $				6,000	$ 126,572
Share-based Payment Arrangement, Option [Member]
Share-based Payment Arrangement, Expense | $				$ 0	$ 26,652
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio		2,000	500
Conversion of Series H Preferred Stock Into Common Stock [Member]
Conversion of Stock, Shares Converted (in shares)				1,686
Conversion of Stock, Shares Issued (in shares)				9,393,937
Conversion of Series I Preferred Stock Into Common Stock [Member]
Conversion of Stock, Shares Converted (in shares)				700
Conversion of Stock, Shares Issued (in shares)				4,087,412
Conversion of Series H and Series I Preferred Stock Into Common Stock [Member]
Conversion of Stock, Shares Issued (in shares)				13,481,349
Series B Convertible Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares				$ 1,000
Preferred Stock, Shares Outstanding, Ending Balance (in shares)				100		100
Convertible Preferred Stock, Conversion Price1 (in dollars per share) | $ / shares				$ 350,000
Series H Convertible Preferred Stock [Member]
Preferred Stock, Shares Outstanding, Ending Balance (in shares)				0		1,686
Series I Convertible Preferred Stock [Member]
Preferred Stock, Shares Outstanding, Ending Balance (in shares)				0		700
Series J Convertible Preferred Stock [Member]
Preferred Stock, Shares Outstanding, Ending Balance (in shares)				300
Convertible Preferred Stock, Conversion Price1 (in dollars per share) | $ / shares	$ 2
Stock Issued During Period, Shares, New Issues (in shares)	300
Proceeds from Issuance of Preferred Stock and Preference Stock | $	$ 300,000

Note 9 - Stockholders' Equity -

Note 9 - Stockholders' Equity - Preferred Stock Summary (Details) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Preferred stock, shares outstanding (in shares)	400	2,486
Preferred Stock	$ 376,095	$ 1,932,433
Series B Convertible Preferred Stock [Member]
Preferred stock, shares outstanding (in shares)	100	100
Preferred Stock	$ 76,095	$ 76,095
Series H Convertible Preferred Stock [Member]
Preferred stock, shares outstanding (in shares)	0	1,686
Preferred Stock		$ 1,156,338
Series I Convertible Preferred Stock [Member]
Preferred stock, shares outstanding (in shares)	0	700
Preferred Stock		$ 700,000
Series J Convertible Preferred Stock [Member]
Preferred stock, shares outstanding (in shares)	300
Preferred Stock	$ 300,000

Note 9 - Stockholders' Equity_3

Note 9 - Stockholders' Equity - Summary of Warrants (Details)	Mar. 31, 2020$ / sharesshares
Series G Warrants [Member]
Exercise price (in dollars per share) | $ / shares	$ 25,440
Number of warrants (in shares) | shares	48
Series H Warrants [Member]
Exercise price (in dollars per share) | $ / shares	$ 1.15
Number of warrants (in shares) | shares	217,392
Series I Warrants [Member]
Exercise price (in dollars per share) | $ / shares	$ 15,000
Number of warrants (in shares) | shares	48

Note 10 - Income Taxes (Details

Note 10 - Income Taxes (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Income Taxes Paid	$ 0	$ 0

Note 11 - Grants and Collabor_2

Note 11 - Grants and Collaboration Revenue (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Revenue from Contract with Customer, Including Assessed Tax	$ 715,977	$ 364,232
Unused Grant Funds	606,944
NIH Grants [Member]
Revenue from Contract with Customer, Including Assessed Tax	654,021	354,319
Research Agreements [Member]
Revenue from Contract with Customer, Including Assessed Tax	$ 61,956	$ 9,913

Note 12 - Subsequent Events (De

Note 12 - Subsequent Events (Details Textual) - Subsequent Event [Member]	Apr. 17, 2020USD ($)
Proceeds From Paycheck Protection Program Under CARES Act	$ 170,200
Paycheck Protection Program Loan [Member]
Debt Instrument, Periodic Payment, Total	$ 9,578.16